Share on StockTwits

Evotec AG (NASDAQ:EVTC) CEO Peter Harrington sold 50,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $25.05, for a total value of $1,252,500.00. Following the sale, the chief executive officer now directly owns 230,988 shares of the company’s stock, valued at approximately $5,786,249. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Evotec AG (NASDAQ:EVTC) traded down 0.36% during mid-day trading on Wednesday, hitting $24.77. 124,096 shares of the company’s stock traded hands. Evotec AG has a one year low of $20.64 and a one year high of $26.33. The stock has a 50-day moving average of $23.79 and a 200-day moving average of $24.16. The company’s market cap is $1.941 billion.

Evotec AG (NASDAQ:EVTC) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.01. The company had revenue of $87.20 million for the quarter, compared to the consensus estimate of $91.26 million. The company’s revenue for the quarter was down .1% on a year-over-year basis. On average, analysts predict that Evotec AG will post $1.68 earnings per share for the current fiscal year.

Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.